NCT05150652View on ClinicalTrials.gov

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2036

Conditions
Breast CancerHER2-negative Breast CancerNode-negative Breast CancerBreast Carcinoma
Interventions
DRUG

Anastrozole 1mg

Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.

DRUG

Letrozole 2.5mg

Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.

DRUG

Exemestane 25 mg

Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.

DRUG

Tamoxifen

Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.

Trial Locations (1)

40536

RECRUITING

University of Kentucky Markey Cancer Center, Lexington

All Listed Sponsors
lead

Irada Ibrahim-zada

OTHER